The company has been making investments in rare cultivars and expanding its international presence in other countries as well in recent days. In May, Organigram announced its first-ever investment in the United States in which it provided $8 million to Oregon's Phylos Bioscience to help commercialize tetrahydrocannabivarin (THCV) gummies and vapes — expected to be available by the end of this year. Earlier in May, Organigram entered Germany's medical cannabis market through a supply agreement with Berlin's Sanity Group. The company now has supply agreements in the U.K., Germany, Israel and Australia. As the demand for medical cannabis grows in the U.K. the market for certain cannabinoids like cannabigerol (CBG) is expected to expand rapidly there in the coming years.